Sensus Healthcare, Inc. (NASDAQ:SRTS – Get Free Report) has earned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $5.8333.
Several equities analysts have recently weighed in on the company. Lake Street Capital lowered their price target on Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Weiss Ratings cut Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. Wall Street Zen downgraded Sensus Healthcare from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Citigroup restated a “buy” rating on shares of Sensus Healthcare in a research note on Friday, May 8th. Finally, Alliance Global Partners reaffirmed a “buy” rating on shares of Sensus Healthcare in a research report on Monday, August 17th.
Check Out Our Latest Report on SRTS
Institutional Inflows and Outflows
Sensus Healthcare Stock Performance
SRTS opened at $3.34 on Monday. The company’s 50-day simple moving average is $2.99 and its two-hundred day simple moving average is $3.57. The stock has a market capitalization of $54.98 million, a P/E ratio of -3.55 and a beta of 1.10. Sensus Healthcare has a 52-week low of $2.66 and a 52-week high of $5.49.
Sensus Healthcare (NASDAQ:SRTS – Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.41). Sensus Healthcare had a negative net margin of 88.45% and a negative return on equity of 21.57%. The company had revenue of $2.29 million for the quarter, compared to the consensus estimate of $4.60 million.
About Sensus Healthcare
Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.
The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.
See Also
- Five stocks we like better than Sensus Healthcare
- What Rising Delivery Forecasts Say About Rivian’s Stock Prospects
- Deere Earnings: Has the Stock Outrun the Farm Cycle?
- BJ’s Wholesale Club Is Turning Stronger Fundamentals Into a Bullish Setup
- 3 Dividend Stocks Raising Their Payouts as Investors Search for Growth and Income
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
